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The PLoS ONE Editors
Following the publication of the article ‘‘Immune Protection
Induced on Day 10 Following Administration of the 2009 A/
H1N1 Pandemic Influenza Vaccine’’, the Editors of PLoS ONE
noticed that the article described findings from a clinical trial. In
line with PLoS ONE’s editorial policies for clinical trials; the article
should have included a trial registration number for the study and
a copy of the trial protocol.
The Editors followed up on this matter with the authors, who
indicated that the trial had not been registered at a public registry.
The Editors were also concerned about the documentation and
clarifications provided by the authors in response to the request for
the study protocol and details on ethical approval for the study. In
the light of the concerns raised in relation to the article, the Editors
contacted the Institut Pasteur of Shanghai to request an
institutional investigation into the research reported in the article.
The Institut Pasteur of Shanghai has now completed their
institutional investigation. While the investigation has not ques-
tioned the results reported in the article, the enquiry has revealed
concerns about some aspects of the study. In the light of the
findings of this enquiry, the Editors issue this expression of concern
to make readers aware of the following concerns in relation to
this trial:
N The article reports that the clinical component of the study was
approved by the Institutional Review Board of Institut Pasteur
of Shanghai. However, the investigation committee has stated
that the clinical study was in fact approved by the Henan CDC
Ethics Committee.
N The Editors feel that the reporting of the clinical trial in the
article is inadequate given that no information is provided
regarding the setting for recruitment of the participants. The
investigation committee has reported that the participants in
the study were employees of Hualan Biological Bacterin
Company, China, which is one of the funders of the study, the
manufacturer of the vaccine tested, and the employer of
several of the authors.
N The article reports that 58 subjects were recruited for the
study, however, the institutional investigation established that
approximately 130 volunteers were recruited, while only 58
completed the full protocol.
N As outlined above, the clinical study was not registered as a
clinical trial. PLoS ONE supports the position of the
International Committee of Medical Journal Editors (ICMJE)
on trial registration and follows the WHO definition of a
clinical trial, which constitutes : ‘‘...any research study that
prospectively assigns human participants or groups of humans to one or
more health-related interventions to evaluate the effects on health
outcomes.’’ In this study participants were prospectively
recruited, received a vaccine against the 2009 A/H1N1
influenza virus and their immune response was evaluated
following vaccination. We consider the vaccination to be
health-related intervention and the measurement of the
immune response to constitute a health outcome, and as a
result, the Editors consider that the study fulfills the criteria for
a public repository.
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